| |
| |
|
| Insider
Information: |
Column Group Ii Gp, Lp |
| Relationship: |
10% Owner |
| City: |
San Francisco |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
2 |
|
| Direct
Shares |
800,000 |
|
|
Indirect Shares
|
1,000 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$1,540 |
|
|
| Total
Shares |
801,000 |
|
|
| Total
Value |
$1,540 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
59
|
0
|
|
Stock
price went up :
|
24
|
0
|
| Stock
price went down : |
35
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 -3.1%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Immune Design Corp. |
IMDZ |
10% Owner |
2016-09-20 |
800,000 |
|
0 |
Premium* |
|
|
Ngm Biopharmaceuticals Inc |
NGM |
10% Owner |
2024-04-05 |
0 |
2024-04-05 |
1,000 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
78 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 4
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| IMDZ |
Immune Design Corp. |
10% Owner |
– – • |
2016-09-20 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
800,000 |
|
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2019-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
475,957 |
|
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-01-24 |
4 |
B |
$0.00 |
$0 |
I/I |
250,000 |
8,250 |
1.42 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-01-25 |
4 |
B |
$0.00 |
$0 |
I/I |
599,701 |
28,041 |
1.42 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2022-05-13 |
4 |
B |
$0.00 |
$0 |
I/I |
129,365 |
41,577 |
1.42 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
I/I |
(10,640,080) |
0 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2024-04-05 |
4 |
D |
$0.00 |
$0 |
D/D |
(11,103,333) |
0 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2024-04-05 |
4 |
A |
$0.00 |
$0 |
I/I |
1,000 |
1,000 |
0 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2019-11-11 |
4 |
B |
$12.00 |
$180 |
D/D |
15 |
253,922 |
2.37 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-12-12 |
4 |
B |
$4.98 |
$1,493 |
I/I |
300 |
380,472 |
1.42 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2023-01-20 |
4 |
B |
$5.00 |
$2,498 |
I/I |
500 |
733,059 |
1.42 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– – • |
2023-11-16 |
4 |
B |
$0.62 |
$3,627 |
I/I |
5,840 |
949,862 |
0.01 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
|
– – • |
2023-11-15 |
4 |
B |
$0.71 |
$11,880 |
I/I |
16,791 |
944,022 |
0.01 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-07-30 |
4 |
B |
$17.99 |
$13,169 |
D/D |
732 |
1,617,684 |
2.37 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-11-22 |
4 |
B |
$5.00 |
$21,646 |
I/I |
4,330 |
380,172 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2019-10-23 |
4 |
B |
$11.86 |
$24,752 |
D/D |
2,087 |
245,498 |
2.37 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2019-08-02 |
4 |
B |
$13.97 |
$24,898 |
D/D |
1,782 |
2,367,018 |
2.37 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2023-01-12 |
4 |
B |
$4.95 |
$26,603 |
I/I |
5,378 |
694,920 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2019-10-22 |
4 |
B |
$12.00 |
$27,600 |
D/D |
2,300 |
243,411 |
2.37 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-03-25 |
4 |
B |
$12.49 |
$30,176 |
D/D |
2,416 |
1,038,170 |
2.37 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2019-08-01 |
4 |
B |
$13.98 |
$36,346 |
D/D |
2,600 |
2,365,236 |
2.37 |
- |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2022-05-27 |
4 |
B |
$13.45 |
$36,453 |
I/I |
2,710 |
51,760 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
10% Owner |
– – • |
2023-01-30 |
4 |
B |
$5.00 |
$37,707 |
I/I |
7,542 |
750,501 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2023-01-23 |
4 |
B |
$5.00 |
$49,494 |
I/I |
9,900 |
742,959 |
1.5 |
% |
|
| NGM |
Ngm Biopharmaceuticals In... |
General Partner |
– – • |
2020-02-26 |
4 |
B |
$18.00 |
$67,518 |
D/D |
3,751 |
302,573 |
2.45 |
% |
|
78 Records found
|
|
Page 1 of 4 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
